Clearpoint Neuro Inc (CLPT)

Currency in USD
15.14
-0.41(-2.64%)
Closed·
15.30+0.16(+1.06%)
·
Advertisement
CLPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.0615.57
52 wk Range
8.2730.10
Key Statistics
Prev. Close
15.14
Open
15.56
Day's Range
15.06-15.57
52 wk Range
8.27-30.1
Volume
414.65K
Average Volume (3m)
720.56K
1-Year Change
44.3279%
Book Value / Share
0.36
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLPT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
23.50
Upside
+55.22%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Clearpoint Neuro Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 23.50
(+55.22% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy22.00+45.31%25.00Maintain04/08/2026
Stifel
Buy25.00+65.13%16.00Maintain18/06/2026
B.Riley
Buy30.00+98.15%20.00Maintain18/06/2026
Stifel
Buy16.00+5.68%16.00Maintain09/06/2026
Stifel
Buy16.00+5.68%16.00Maintain14/05/2026

Clearpoint Neuro Inc Earnings Call Summary for Q2/2026

  • Clearpoint Neuro Q2 2026 revenue rose 18% YoY to $10.9M but missed estimates by 14.4%; EPS loss of $0.38 exceeded forecast by $0.09.
  • Shares plunged 15.5% after-hours to $13 following the dual miss; operating expenses surged 68% in sales/marketing, 64% in G&A.
  • Management issued 2026 revenue guidance of $48M-$52M, shifting focus to clinical support and new CAL facility over traditional device sales.
  • New California CAL facility could generate $60M+ annually at capacity; first GLP work expected H1 2027 with commercial launches from partners.
  • Cash fell to $29.4M from $45.9M year-end 2025; CEO signals pivot to B2B pharma model potentially representing half of future revenue.
Last Updated: 03/08/2026, 22:30
Read Full Transcript

Earnings

Latest Release
03/08/2026
EPS / Forecast
-0.38 / -0.29
Revenue / Forecast
10.9M / 12.73M
EPS Revisions
Last 90 days

Compare CLPT to Peers and Sector

Metrics to compare
CLPT
Peers
Sector
Relationship
P/E Ratio
−13.4x−11.0x−0.4x
PEG Ratio
0.28−0.190.00
Price/Book
42.9x4.8x2.6x
Price / LTM Sales
10.9x2.3x3.1x
Upside (Analyst Target)
55.2%54.8%49.4%
Fair Value Upside
Unlock−4.4%6.8%Unlock

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.44M14.57%69.11M
Other Institutional Investors
15.40M50.50%239.54M
Public Companies & Retail Investors
10.66M34.93%165.69M
Total
30.5M100.00%474.34M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.80%2,379,80437,006
MAK Capital Fund L.P.7.79%2,375,86136,945

People Also Watch

5.080
ABUS
+0.20%
4.010
MNKD
+1.52%
29.01
CLFD
-1.76%
582.53
CW
-2.32%

FAQ

What Is the Clearpoint Neuro (NASDAQ: CLPT) Share Price Today?

The Clearpoint Neuro stock price today is 15.14 USD.

What Stock Exchange Does Clearpoint Neuro (CLPT) Trade On?

Clearpoint Neuro is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Clearpoint Neuro?

The stock symbol (also called a 'ticker') for Clearpoint Neuro is "CLPT."

What Is the Current Clearpoint Neuro Market Capitalisation?

As of today, Clearpoint Neuro (NASDAQ: CLPT) market cap is 461.83M USD.

What Is Clearpoint Neuro's (CLPT) Earnings Per Share (TTM)?

The Clearpoint Neuro EPS is currently -1.18 (Trailing Twelve Months).

When Is the Next Clearpoint Neuro Earnings Date?

Clearpoint Neuro's next earnings report will be released on 05/11/2026.

Is CLPT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Clearpoint Neuro moving averages and other technical indicators, the daily buy/sell signal for CLPT stock is Neutral.

How Many Times Has Clearpoint Neuro Stock Split?

Clearpoint Neuro has split 1 times. (See the CLPT stock split history page for full effective split date and price information.)

How Many Employees Does Clearpoint Neuro Have?

Clearpoint Neuro has 172 employees, based on their latest Companies House report.

What is the current trading status of Clearpoint Neuro (NASDAQ: CLPT)?

As of 01/09/2026, Clearpoint Neuro (CLPT) is trading at a share price of 15.14 USD, with a previous close of 15.14 USD. The stock has fluctuated within a day range of 15.06 USD to 15.57 USD, while its 52-week range spans from 8.27 USD to 30.10 USD.

What Is Clearpoint Neuro (CLPT) Price Target According to Analysts?

The average 12-month price target for Clearpoint Neuro is 23.50 USD, with a high estimate of 25 USD and a low estimate of 22 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +55.22% Upside potential.

What Is the CLPT After Hours Price?

CLPT's last after hours stock price is 15.30 USD, the stock has decreased by 0.16, or 1.06%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.